Results 71 to 80 of about 70,191 (302)

CAQ Corner: Immune‐mediated complications

, 2022
Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley   +1 more source

Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci

Nature Communications
Genome-wide association studies of primary sclerosing cholangitis have identified 23 susceptibility loci. The majority of these loci reside in non-coding regions of the genome and are thought to exert their effect by perturbing the regulation of nearby ...
Elizabeth C. Goode, Laura Fachal, Nikolaos Panousis, Loukas Moutsianas, Rebecca E. McIntyre, Benjamin Yu Hang Bai, Norihito Kawasaki, Alexandra Wittmann, Tim Raine, Simon M. Rushbrook, Carl A. Anderson   +10 more
doaj   +1 more source

Chemokine receptor-5Delta32 mutation is no risk factor for ischemic-type biliary lesion in liver transplantation [PDF]

, 2009
It has been shown that certain chemokine receptor polymorphisms may correspond to certain complications after organ transplantation. Ischemic-type biliary lesion (ITBL) encounters for major morbidity and mortality in liver transplant recipients.
Christian Moench, Mönch, Christian, Peter Neuhaus, Christoph Heidenhain, Gero Puhl, Anja Lautem, Puhl, Gero, Neuhaus, Peter, Lautem, Anja, Heidenhain, Christoph   +9 more
core   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source

Postoperative association between impaired renal function and vascular dysfunction in liver transplant recipients

, 2022
Liver Transplantation, EarlyView.
Domenico A. Chavez, Marie‐Claire Evans, Natalie J. Bohmke, Hiba Kamal, Loan Quynh Tran, Chandra Bhati, Susan Wolver, Mohammad S. Siddiqui, Danielle L. Kirkman   +8 more
wiley   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

Primary sclerosing cholangitis

Digestive Diseases, 2010
Primary sclerosing cholangitis (PSC) is a chronic, cholestatic liver disease caused by diffuse inflammation and fibrosis that can involve the entire biliary tree. It is a progressive disorder which can ultimately lead to biliary cirrhosis, portal hypertension and hepatic failure. PSC is a complex genetic disorder with male predominance.
Williamson, K, Chapman, R
openaire   +5 more sources

Autoimmune Cholangitis: Is It an Antimitochondrial Antibody Negative Primary Biliary Cirrhosis? [PDF]

, 1999
Autoimmune cholangitis/cholangiopathy (AIC) is a recently described disease characterized by chronic cholangitis resembling primary biliary cirrhosis (PBC) with a high frequency of antinuclear antibodies (ANA) and with sero-negativity for ...
Omagari, Katsuhisa
core  

Immunoglobulin G subtypes-1 and 2 differentiate immunoglobulin G4-associated sclerosing cholangitis from primary sclerosing cholangitis

, 2020
Background Autoimmune pancreatitis is a special form of chronic pancreatitis with strong lymphocytic infiltration and two histopathological distinct subtypes, a lymphoplasmacytic sclerosing pancreatitis and idiopathic duct centric pancreatitis ...
Valente, Roberto, Löhr, J.-Matthias, Maetzel, Hartwig, Verbeke, Caroline Sophie, Hartwig Maetzel, Maier, Pia, Haas, Stephan L., Roberto Valente, Karouk Said, Caroline S Verbeke, Pia Maier, Maisonneuve, Patrick, J‐Matthias Löhr, Raffaella Pozzi‐Mucelli, Pozzi-Mucelli, Raffaella, Said, Karouk, Patrick Maisonneuve, Moro, Carlos F., Miroslav Vujasinovic, Vujasinovic, Miroslav, Stephan L Haas, Carlos F Moro   +21 more
core   +1 more source

Does ursodeoxycholic acid change the proliferation of the colorectal mucosa? A randomized, placebo-controlled study [PDF]

, 2003
Background: In animal models ursodeoxycholic acid (UDCA) showed a chemoprotective effect against colon cancer. To explain this, a reduced proliferation of the colorectal mucosal proliferation was suggested.
Burkhard Göke, Marsteller, I., Paumgartner, Gustav, Göke, B., Ochsenkühn, Thomas, Thomas Ochsenkühn, Hay, U., Igor Marsteller, Sackmann, M., Michael Sackmann, Joachim Diebold, Diebold, J., Ulrich Hay, Gustav Paumgartner   +13 more
core   +1 more source